JGC
SLNO

J. Goldman & Co’s Soleno Therapeutics SLNO Stock Holding History

J. Goldman & Co’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-67,600
Closed -$4.83M – 622
2025
Q1 		$4.83M Buy
+67,600
New +$3.29M 0.12% 211

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

J. Goldman & Co's SLNO Position: Q4 2025 in Review

J. Goldman & Co sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 19,658 shares — an estimated $1.33M sold.

J. Goldman & Co first reported a position in SLNO in Q4 2019 and held it in 17 quarters. The position peaked at $3.57M in Q2 2025. 247 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • J. Goldman & Co reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 19,658 Soleno Therapeutics shares in Q4 2025, an estimated $1.33M.
  • J. Goldman & Co first reported a position in Soleno Therapeutics in Q4 2019 and held it in 17 quarters.
  • J. Goldman & Co's Soleno Therapeutics position peaked at $3.57M in Q2 2025.
  • 247 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.